Tevogen Bio Holdings Inc.
TVGN
$7.00
-$2.54-26.63%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -68.36% | -54.77% | -7.29% | -38.66% | -17.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.85% | -50.76% | -5.85% | -36.68% | -64.91% |
| Operating Income | 47.85% | 50.76% | 5.85% | 36.68% | 64.91% |
| Income Before Tax | 47.47% | 50.47% | 2.67% | 43.04% | -192.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.47% | 50.47% | 2.67% | 43.04% | -192.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.47% | 50.47% | 2.67% | 43.04% | -192.03% |
| EBIT | 47.85% | 50.76% | 5.85% | 36.68% | 64.91% |
| EBITDA | 47.94% | 51.17% | 5.23% | 37.45% | 65.00% |
| EPS Basic | 50.45% | 46.81% | 13.88% | 22.33% | -185.06% |
| Normalized Basic EPS | 51.36% | 48.55% | 15.51% | 52.36% | 70.30% |
| EPS Diluted | 50.45% | 46.81% | 13.88% | 23.48% | 74.99% |
| Normalized Diluted EPS | 51.36% | 48.55% | 15.51% | 52.36% | 69.21% |
| Average Basic Shares Outstanding | 8.00% | -3.74% | 15.19% | 19.55% | 17.53% |
| Average Diluted Shares Outstanding | 8.00% | -3.74% | 15.19% | 19.55% | 13.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |